Pfizer, Prasugrel and New Cardiovascular Drugs
Posted Oct 02, 2008
at 12:52 PM, EDT
This week Pfizer announced its plans to stop CV development; last week the FDA announced they still were not in a position to approve prasugrel. Where is CV drug development headed?
See:
FDA once again postpones decision on prasugrel
Pfizer to drop development of drugs for hyperlipidemia, atherosclerosis, and heart failure
Previous postsBillets précédents
JUPITER: How will it change your practice?
24 comments24 commentaires |
Posted Nov 09, 2008
at 03:50 PM, EDT by Steven Publié le 11.09.2008 à 15h50 par Steven
at 03:50 PM, EDT by Steven Publié le 11.09.2008 à 15h50 par Steven
Who's talking
|
Eric J Topol MD
Director, Scripps Translational Science Institute (STSI) Dean, Scripps School of Medicine Chief Academic Officer, Scripps Health La Jolla, CA |
General links
The moderator of this blog has compiled the following series of relevant articles:
- A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure
- "Genetic beta blockade" identified in some blacks
- New York Times: CT angiography may be overused due to profit "incentive" [HeartWire > MediaPulse]; July 01, 2008
- CMS moves to halt Medicare reimbursement of CT angiography, except in clinical trials . [HeartWire > News]; January 11, 2008
- CTA in the ER can safely and effectively screen for ACS.
- SLCO1B1 Variants and Statin-Induced Myopathy -- A Genomewide Study.
- Genetic variants associated with risk of statin-induced myopathy
CommentsCommentaires